<DOC>
	<DOCNO>NCT00427375</DOCNO>
	<brief_summary>Patients T2T3 low rectal cancer ( size = &lt; 4 cm ) receive neoadjuvant treatment ( 50Gy 5 week concomitant chemotherapy . Good responder ( residual tumour = &lt; 2 cm ) randomise local v rectal excision , 6-8 week treatment . The composite end point evaluate rate patient death , recurrence , major morbidity severe effect two year .</brief_summary>
	<brief_title>Local Excision Downstaged Rectal Cancer</brief_title>
	<detailed_description>Rectal excision standard surgical treatment rectal cancer . The risk mortality major short long term morbidity induce rectal excision justifies new treatment . Local excision conservative alternative approach associate low mortality morbidity . The purpose prospective randomise multicenter study compare local v rectal excision good responder radiochemotherapy low rectal cancer . Patients T2T3 low rectal cancer , less 8 cm anal verge , size = &lt; 4 cm , receive neoadjuvant treatment , include radiotherapy 45-55Gy 5 week concomitant chemotherapy consist least , one fluoropyrimidine . Good clinical responder ( residual tumour = &lt; 2 cm ) randomise local v rectal excision , 6-8 week treatment . In case confirm pathological response follow local excision , complementary rectal excision require . Bad responder ( residual tumour &gt; 2cm ) treat primary rectal excision . Follow-up include digital rectal examination , CT-scan endorectal ultrasound ( local excision ) every 4 month 2 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>T2T3 low adenocarcinoma rectum Tumour size = &lt; 4cm Less 8 cm anal verge No metastatic disease Patient least 18 year age ECOG performance status score = &lt; 2 Patient doctor sign informed consent inclusion criterion : Residual clinical tumour size = &lt; 2cm radiochemotherapy T1 , T4 tumour anal sphincter invasion Metastatic disease ( M1 ) Contra indication radiotherapy and/or fluoropyrimidine use chemotherapy History cancer Symptomatic cardiac coronary insufficiency Severe renal insufficiency Peripheral neuropathy Patient include trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rectal cancer surgery</keyword>
	<keyword>Neoadjuvant radiochemotherapy</keyword>
	<keyword>Randomized clinical trial</keyword>
	<keyword>Multicenter study</keyword>
</DOC>